Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?

dc.contributor.authorPeseski, Andrew M.
dc.contributor.authorSaliba, Antoine N.
dc.contributor.authorAlthouse, Sandra K.
dc.contributor.authorSayar, Hamid
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2023-01-20T22:12:35Z
dc.date.available2023-01-20T22:12:35Z
dc.date.issued2021
dc.description.abstractBACKGROUND: Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are a group of hematologic malignancies with known vascular complications. The role race and ethnicity play in these complications is less defined. We aimed to further evaluate the role of race in patients without a history of previous thrombotic or hemorrhagic events. METHODS: In this retrospective study, 300 adult patients with MPN were included; 270 (90.0%) were White and 30 (10.0%) were non-White. The non-White group primarily consisted of African American or Black (26 patients), followed by others. Median age at diagnosis was 58 years for White patients and 61.5 years for non-White patients. The interaction between outcomes and vascular events with race was evaluated using multivariate logistical regression models. RESULTS: The incidence of thrombotic events was inversely correlated with age at diagnosis, with younger patients demonstrating a higher rate of thrombotic events over time (p < .001). The incidence of thrombotic or hemorrhagic events did not differ between White and non-White patients. A statistically significant difference in median survival was observed between White and non-White patients: 29 years (95% confidence interval [CI]: 21.8-not reached) versus 13 years (95% CI: 5.7-22.7), respectively (p = .016). CONCLUSION: This study did not find a significant difference in the rate of thrombotic or hemorrhagic events between White and non-White patients with MPN but suggested that non-White patients had significantly shorter median survival than White patients. Such observations may inform future studies to further characterize racial disparities in outcomes.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationPeseski, A. M., Saliba, A. N., Althouse, S. K., & Sayar, H. (2021). Does race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms? Hematology/Oncology and Stem Cell Therapy, S1658-3876(21)00005-4. https://doi.org/10.1016/j.hemonc.2021.01.005en_US
dc.identifier.issn1658-3876en_US
dc.identifier.urihttps://hdl.handle.net/1805/31003
dc.language.isoen_USen_US
dc.relation.isversionof10.1016/j.hemonc.2021.01.005en_US
dc.relation.journalHematology/Oncology and Stem Cell Therapyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourcePublisheren_US
dc.subjectEssential thrombocythemiaen_US
dc.subjectMyelofibrosisen_US
dc.subjectVascular outcomesen_US
dc.titleDoes Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Peseki2021DoesRace-CCBYNCND.pdf
Size:
600.51 KB
Format:
Adobe Portable Document Format
Description:
Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: